Skip to content
Danish biotech alliance behind enzyme master stroke

Press release -

Danish biotech alliance behind enzyme master stroke

Groundbreaking new enzyme solution from Chr. Hansen and Novozymes allows cheese manufacturers to add value to the whey stream and save cheese dry matter.

The Chr. Hansen/Novozymes strategic alliance which was formed in 2002 debuts a new solution marketed under the name LactoYIELD™. LactoYIELD™ converts lactose into lactobionic acid, LBA, in an enzymatic process. An advanced enzyme innovation with unique opportunities both inside and outside the food area.

“Jointly, Chr. Hansen and Novozymes have developed a process that enables industrial application of lactose oxidase, a member of the cellobiose oxidase enzyme class,” explains Per Munk Nielsen, Senior Science Manager, Novozymes. “The proprietary enzyme and enzymatic process enable 100% conversion of lactose — of which the biggest cheese producers out there have a lot — into LBA. Until today LBA has been produced by costly non-enzymatic chemical reactions and primarily in the pharmaceutical and cosmetics areas.”

Proof of concept

Treading new ground, the enzyme alliance has proof of concept within cheese production. “This new, proprietary process allows cost-effective manufacturing of large amounts of LBA from the whey stream in a cheese processing plant,” explains Hans Christian Bejder, Marketing Director, Chr. Hansen. “LBA can be added as a dry matter into pizza cheese without influencing the properties of the cheese.”

“In other words,” Bejder continues, “the value of lactose becomes the same as the value of cheese dry matter. The return on this application is very high and can easily justify investments required even at relatively low pizza cheese volumes.”

The business case

The benefit for the dairies lies within the difference between the pizza cheese price and the lactose market price: LBA in pizza cheese has the opportunity to generate significantly more value for the cheese maker than selling the pure lactose can.

“Currently,” says Bejder, “the value of lactose powder is approx. 15 times lower than the value of pizza cheese dry matter. The pizza cheese manufacturers get more cheese out of the same amount of milk while at the same time increasing the value of their whey. Playing with the idea that this concept is applied to the 2.5 million ton pizza cheese produced world-wide then 100.000 tons of extra cheese can be made with the same amount of milk used today.”

Other promising application areas

There are many other potential applications of enzymatic LBA in and outside food, including:

  • Cheese, besides from pizza cheese: Low cost dairy-based dry matter in other cheese types;
  • Ice-cream: Potential improvement of melt ability and replacement of SMP;
  • Milk and other beverages: Salts of LBA such as Ca-LBA and K-LBA are highly soluble in aqueous solutions and therefore interesting candidates for mineral fortification of milk, soft drinks and juices;
  • Meat industry: Reduce water loss in meat products during freeze/thaw and cooking processes;
  • Pharmaceutical use: LBA has unique function on cell surfaces and has shown potential use in wound healing products



International partners wanted

The alliance is now looking for selected partners to further explore and develop proof of concept in new and promising applications for LBA other than pizza cheese. Simultaneously regulatory approvals in markets where LBA is not yet approved as a food ingredient will be addressed.


The ‘Milky Way Alliance’


In 2002 the two world leaders in enzyme innovation — Chr. Hansen and Novozymes — formed a strategic alliance, the ‘Milky Way Alliance’. The purpose was to bring valuable enzyme solutions to the dairy industry. By teaming up with the industry, the alliance develops advanced enzyme solutions based on the complementary technologies of two innovation leaders. In 2005 the alliance launched YieldMAX™, an advanced enzyme solution which offers increased yield for manufacturers of pasta filata types of cheeses.

Topics


Chr. Hansen is a global bioscience company that develops natural ingredient solutions for the food, nutritional, pharmaceutical and agricultural industries. The products include cultures, enzymes, probiotics and natural colors, and all solutions are based on strong research and development competencies coupled with significant technology investments. Revenue in the 2013/14 financial year was EUR 756 million. The company holds a leading market position in all its divisions: Cultures & Enzymes, Health & Nutrition and Natural Colors. It has more than 2,500 dedicated employees in over 30 countries and main production facilities in Denmark, France, USA and Germany. Chr. Hansen was founded in 1874 and is listed on NASDAQ OMX Copenhagen.

Contacts

Helle Rexen

Helle Rexen

Press contact Media relations officer +45 20 74 28 40

About us

Chr. Hansen is a global, differentiated bioscience company that develops natural ingredient solutions for the food, nutritional, pharmaceutical and agricultural industries. At Chr. Hansen we are uniquely positioned to drive positive change through microbial solutions. We have worked for over 150 years to enable sustainable agriculture, better food and healthier living for more people around the world. Our microbial and fermentation technology platforms, including our broad and relevant collection of around 50,000 microbial strains, have game-changing potential. Matching customer needs and global trends we continue to unlock the power of good bacteria to respond to global challenges such as food waste, global health and the overuse of antibiotics and pesticides. As one of the world’s most sustainable companies, we touch the lives of more than 1 billion people every day. Driven by our legacy of innovation and curiosity to pioneer science, our purpose – To grow a better world. Naturally. – is at the heart of everything we do.

Chr. Hansen Holding A/S

Boege Allé 10-12
DK-2970 Hoersholm
Denmark